Today: 27 January 2026
Subscribe
Browse Category

Biotech Industry News 7 January 2026 - 21 January 2026

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

New York, January 21, 2026, 05:22 EST — Premarket Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase. (Public) Novavax’s deal is significant as the company looks to pivot its platform toward steadier revenue sources amid…
21 January 2026
······
Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug

Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug

ZURICH, Jan 17, 2026, 18:33 CET — Market closed. Novartis AG (NVS) shares ended Friday on a positive note after the Swiss pharma giant revealed that U.S. regulators awarded fast-track designation to its ianalumab programme. This move brings immunology back into focus ahead of the company’s earnings report. (MarketScreener) The FDA’s Breakthrough Therapy designation is designed to accelerate the development…
17 January 2026
····
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

New York, January 17, 2026, 07:32 EST — Market closed. Shares of Pfizer Inc (PFE) closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight. The next real hurdle for the stock arrives Tuesday. U.S. markets shut Monday for Martin Luther…
17 January 2026
·····
Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

New York, Jan 14, 2026, 14:09 EST — Regular session Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end. This matters since Nuvalent remains a clinical-stage company. Investors want a clearer timeline for its first possible U.S.…
14 January 2026
····
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

New York, Jan 14, 2026, 08:52 EST — Premarket NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide…
14 January 2026
·····
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as…
13 January 2026
·····
Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

New York, Jan 12, 2026, 15:14 (EST) — Regular session Mesoblast Ltd’s shares on the U.S. market dropped roughly 11% Monday, sliding to $18.64 in afternoon trading after hitting $20.14 earlier. The Australian biotech’s stock has seen sharp swings since it started highlighting early commercial progress for its main cell therapy. The pullback is significant since Mesoblast has moved beyond…
12 January 2026
····
Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

New York, Jan 10, 2026, 19:48 EST — Market closed Shares of Liquidia Corp surged 12.9% on Friday, closing at $35.86 following a preliminary sales update on its pulmonary hypertension drug YUTREPIA. The company also reported positive cash flow in Q4. During the session, the stock hit a high of $38.07 and was trading about 1.5% higher in after-hours, per…
11 January 2026
·····
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

New York, Jan 10, 2026, 14:37 EST — Market closed Merck & Co (MRK) closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion. (Reuters) Timing is crucial. As Merck faces patent losses on its blockbuster cancer drug Keytruda…
10 January 2026
·····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

New York, January 9, 2026, 17:15 ET — After-hours Revolution Medicines shares jumped 10.7% to $118.64 in after-hours trading on Friday, after the Financial Times reported Merck was in advanced talks to buy the cancer-drug developer for $28 billion to $32 billion. The stock swung between $109.88 and $125.79 in the session on volume of about 20.6 million shares. (Financial…
9 January 2026
·····
Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

New York, Jan 7, 2026, 20:51 EST — Market closed Regeneron Pharmaceuticals shares climbed 4.6% on Wednesday after Bank of America upgraded the drugmaker to “Buy” from “Underperform” and raised its price objective to $860. Investing The call matters because Regeneron’s stock has been stuck in a tug-of-war: investors want proof the company can defend its eye-medicine franchise as rivals…
8 January 2026
·····
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. Reuters For AbbVie, a takeover would also sharpen its push to add new…
7 January 2026
····
1 2 3 4

Stock Market Today

  • Sensex, Nifty Open Lower Amid FII Selling, Await India-EU FTA Announcement
    January 26, 2026, 11:36 PM EST. The Indian equity markets opened lower on Tuesday, with Sensex down 436 points and Nifty slipping 110 points as foreign institutional investors (FIIs) continued to sell. The market awaits the announcement of a Free Trade Agreement (FTA) between India and the European Union at the India-EU Summit, expected to boost sentiment in pharma, textiles, and chemicals sectors. Most sectoral indices traded in the red except metals and PSU banks, with auto, realty, and media sectors leading losses. Support levels for Nifty are seen around 25,000, resistance near 25,250-25,300. U.S. hinted at easing tariffs on Indian imports linked to Russian oil purchases, while China's industrial profits rose in 2025. Investors also monitor over 200 Q4 earnings and the upcoming Union Budget on February 1.
Go toTop